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S UMM A R Y
OB J E C T I V E : To evaluate the diagnostic performance of
Xpertw MTB/RIF on stool samples from children with
clinical suspicion of pulmonary tuberculosis (PTB) at
primary care clinics.
DE S I GN : A cross-sectional diagnostic evaluation enroll-
ing 5–16 year olds from whom one induced sputum (IS)
sample was tested for microbiological TB confirmation.
Results of a single stool sample tested using Xpert were
compared against microbiologically confirmed TB,
defined as a positive result on sputum microscopy and/
or culture and/or IS Xpert.
R E SU LT S : Of 222 children enrolled, 218 had complete
microbiological results. The median age was 10.6 years
(interquartile range 8–13). TB was microbiologically
confirmed in 19/218 (8.7%) children. Of these, respec-
tively 5 (26%), 9 (47%) and 15 (79%) were smear-,
culture- and IS Xpert-positive. Stool Xpert was positive
in 13/19 (68%) microbiologically confirmed cases and
4/199 (2%) microbiologically negative cases. Stool
Xpert detected 76.9% (10/13) of human immunodefi-
ciency virus (HIV) infected and 50% (3/6) of non-HIV-
infected children with microbiologically confirmed TB
(P¼ 0.241).
CONC LU S I ON : Stool Xpert is a potential alternative
screening test for children with suspected TB if sputum is
unavailable. Strategies to optimise the diagnostic yield of
stool Xpert assay need further study.
K E Y WORD S : GeneXpert; faecal specimen; children
CHILDHOOD TUBERCULOSIS (TB) contributes
10% of the total 9 million incident cases worldwide,
with an estimated 136 000 deaths among children.1
The childhood TB burden is largely due to undiag-
nosed and late diagnosis of adult TB, which creates a
reservoir for transmission to children.2
The principal challenge to timely diagnosis of
childhood TB is the difficulty in obtaining spontane-
ously expectorated sputum, necessitating sputum
induction, which requires skill and infrastructure.
Furthermore, sputum from children is often pauciba-
cillary, as children are less likely to form cavitary
lesions in lungs to contain the bacilli.2,3 The
sensitivity of the standard diagnostic tests, sputum
microscopy and culture, is therefore lower. A more
easily accessible sample that can be obtained with
minimal skill at primary health care level and an
alternative diagnostic tool is therefore required for
the diagnosis of TB in children.
Mycobacterium tuberculosis DNA can be detected
by an automated molecular assay, Xpertw MTB/RIF
(Cepheid, Sunnyvale, CA, USA). Automation in-
cludes sample processing, nucleic acid extraction,
polymerase chain reaction (PCR) and the detection of
specific M. tuberculosis codon sequences within a
closed system.4,5 The assay is rapid, producing a
result in 3 h, with little hands-on time in sample
processing.
Previous studies have shown high sensitivity of
Xpert when sputum,6–8 gastric lavage,9,10 broncho-
alveolar lavage11 and nasopharyngeal aspirates12
were used. Xpert was therefore endorsed by the
World Health Organization as an initial test for
diagnosing TB in children. However, invasive proce-
dures are required to obtain such samples.
Stool is a potential sample that can be collected
non-invasively. Children tend to swallow sputum
when they cough and M. tuberculosis DNA has been
shown to survive the harsh acidic and digestive
environment of the gastro-intestinal tract.13 We
therefore evaluated the diagnostic performance of
Xpert using stool in children with clinically suspected
pulmonary TB (PTB) presenting to primary care
clinics in Harare, Zimbabwe. The diagnostic yield of
stool Xpert was assessed against confirmed microbi-
ological PTB determined by testing induced sputum
(IS) with microscopy, solid culture and Xpert.
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METHODS
Participants
Participants were recruited from eight primary care
clinics in Harare between September 2013 and
October 2014, with guardian consent and participant
assent. Participants were children aged 5–16 years
presenting with a chronic cough of.2 weeks and any
one of the classic signs and symptoms of TB,
including weight loss, loss of appetite, persistent
fever without an apparent cause, night sweats or
history of close contact with a TB index patient,
defined as living in close proximity (sharing a room
within a household) with an adult diagnosed with TB
within the preceding 12 months.
Those aged 0–5 years were not included. At the
time of seeking ethical approval, evidence on the
safety and tolerability of sputum induction in
children was requested, as sputum induction is rarely
practised. The available literature did not meet the
satisfaction of the ethical committee to allow the
procedure to be performed in children aged ,5 years.
Participants were excluded if they had an already
confirmed TB diagnosis, had been on anti-tuberculo-
sis treatment for .72 h before enrolment, required
emergency medical attention or were resident outside
Harare.
Study procedures
A questionnaire was used to collect data on demo-
graphics and physical examination. Human immu-
nodeficiency virus (HIV) status was obtained from
documented proof of test result. In case of unknown
HIV status, participants were offered the test through
the clinic’s HIV testing protocols. All participants
were asked to provide a stool sample and to undergo
sputum induction to obtain one sputum sample.
Sputum induction was performed by a trained
nurse following the method described by Zar et al.,14
except where it was contraindicated.15 The procedure
was performed in an open area after a 2–3 h fast. Two
doses of 100 lg salbutamol were administered via an
aerochamber to prevent bronchoconstriction, fol-
lowed by nebulisation with 5% hypertonic saline
for 5 min, or until the participant started to cough.
Oxygen saturation was monitored during and 30 min
after the procedure. IS was collected in a sterile
container by nasopharyngeal suction, if required. If
the participant failed to produce sputum, the proce-
dure was repeated once, 5 min after the first attempt.
The stool sample (about 5 g) was collected into a
wide mouthed specimen collection jar on the spot or
submitted the following day. Samples were transport-
ed at 4–88C to the laboratory within 8 h of collection.
Anti-tuberculosis treatment was commenced by the
residing medical officer at the clinic following
Zimbabwe’s national TB guidelines, in which diag-
nosis is based on clinical history and examination,
chest radiography (CXR) and/or microbiological
results. Study test results on microbiological confir-
mation were made available to the medical officer to
assist in participant management.
Laboratory methods
Sputum was processed for microscopy, culture and
Xpert testing. It was decontaminated by adding an
equal volume of 4% sodium hydroxide for 15 min,
neutralised with phosphate buffered saline (PBS) and
centrifuged at 3200x g for 20 min to obtain a
sediment which was resuspended in 1.5 ml PBS. One
drop of the sediment was used to make a smear,
which was stained using the Ziehl-Neelsen (ZN)
method. All smears were re-read by a second reader
blinded to the first reading. Discordant results were
resolved through a third reading by a different reader.
IS sediment (0.1 ml) was cultured on Lo¨wenstein-
Jensen (LJ) slopes at 378C for 8 weeks, with weekly
monitoring for growth. At least one colony on LJ was
considered to be positive for M. tuberculosis growth,
confirmed by ZN stain and speciation using the SD
Bioline TB Ag MPT64 antigen rapid test (Standard
Diagnostics Inc., Kyonggi, South Korea). Discordant
ZN-positive/MPT64 antigen-negative samples were
speciated using colony morphology, growth at
different temperatures and on para-nitrobenzoic
acid-containing LJ slopes. Confirmed cultures under-
went phenotypic direct drug susceptibility testing
(DST) on LJ slopes for 4 weeks at 378C. For Xpert
testing, 0.5 ml of IS sediment was mixed with 1.5 ml
Xpert reagent, and the mixture was tested according
to the manufacturer’s instructions.
Stool samples were processed within 2 days of
collection, as described by Nicol et al.16 An aliquot of
0.15 g was measured into a centrifuge tube using a
sterile disposable plastic loop that was left inside the
tube; 2.4 ml PBS was then added, and the mixture
was vortexed to remove stool particles from the loop.
The loop was removed and the sample mixture was
left undisturbed at room temperature for 20 min. Two
aliquots of 1 ml supernatant were removed. One
aliquot was used for immediate testing and another
was stored for repeat testing if required. Before
testing, the processed stool sample was centrifuged at
3200x g for 15 min; the sediment was then
resuspended in 1 ml PBS, mixed with 2 ml Xpert
reagent and tested according to the manufacturer’s
instructions. Interpretation of results was auto-
generated by the Xpert system. Personnel carrying
out the index test were blinded to sputum test results.
Data analysis
Sample size was based on an anticipated sensitivity of
the stool Xpert test of 80%, 10% level of precision
and 4% anticipated loss to follow-up. During sample
size computation, no data were available on TB
prevalence among children in our setting; prevalence
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was therefore set at 29%, adopted from a community
study of paediatric TB contacts in South Africa.17
Data were analysed using STATA, version 13.0
(StataCorp, College Station, TX, USA). Descriptive
statistics were used to characterise the study popula-
tion. The v2 test was used to test for associations.
Performance of stool Xpert was assessed as the
proportion of stool Xpert-positive cases among
microbiologically confirmed and clinically diagnosed
TB cases. Microbiological TB was defined as a
positive result on ZN smear microscopy and/or
culture and/or Xpert test on IS. Indeterminate TB
status results and samples without complete data on
index and reference tests were excluded from the
analysis. The study also aimed to evaluate the
performance of stool Xpert in TB clinical case
definitions as defined by Graham et al.18 However,
the number of children who underwent CXR was too
small (n ¼ 24) to provide meaningful classification.
According to the Zimbabwe national TB guidelines, a
CXR is required for children with clinical suspicion of
PTB but without microbiological confirmation; CXR
data were therefore dependent on the clinic’s opera-
tional systems.
Ethics approval for the study was obtained from
the Harare City Health Department, Harare, the
Joint Parirenyatwa Hospital and College of Health
Sciences Research Ethics Committee, Harare, and the
Medical Research Council of Zimbabwe, Harare,
Zimbabwe.
RESULTS
Of the total 222 participants recruited, 4 were
excluded from the analysis: 1 participant was
withdrawn by the guardian, 2 were unable to provide
IS samples and 1 had an IS Xpert test that produced
an error result despite repeated testing. The median
age of the 218 remaining participants was 10.6 years
(interquartile range [IQR] 8–13); 44% were male.
The median Z-scores for weight-for-age and height-
for-age were respectively –1.09 (IQR –1.99 to –0.46)
and –1.88 (IQR –3.70 to –0.73). HIV status was
available for 201 (91%) participants, of whom 111
(51%) were HIV-infected, with 55 (49.5%) undergo-
ing antiretroviral therapy (ART). The distribution of
demographic characteristics between microbiological
TB and no TB groups is shown in Table 1.
Microbiologically confirmed TB
TB prevalence by microbiological confirmation, de-
fined as a positive result on microscopy and/or culture
and/or Xpert testing on IS, was 8.7% (19/218). Five
(26%) of the 19 microbiologically confirmed TB cases
were aged ,10 years. Of the 19 microbiologically
confirmed TB cases, 5 (26%) were smear-positive, 9
(47%) were culture-positive and 15 (79%) were
Xpert-positive on IS. Among smear-positive cases, 2
(40%) were Xpert-positive, culture-positive, 1 (20%)
Xpert-positive, culture-negative and 2 (40%) Xpert-
negative, culture-negative. Only 2/19 (10.5%) micro-
biologically confirmed TB cases were positive on all
three microbiological tests (Figure). Rifampicin resis-
tance was not detected in any of the TB cases by either
direct DST or Xpert testing. A positive HIV status was
documented in 13/19 (68%) microbiological TB cases,
7 (54%) of whom were on ART; 11 (85%) children
tested positive with IS Xpert (Figure). Thirty-two
(14.7%) of 218 children were commenced on anti-
tuberculosis treatment, 19 (59.4%) of whom were
microbiologically confirmed and 13 (40.6%) clinically
diagnosed by a physician.
Diagnostic performance of stool Xpert
Stool Xpert was positive in 17/218 (8.3%) children.
Among HIV-infected children, stool Xpert was
Table 1 Baseline characteristics of TB and non-TB child
patients (n¼ 218)
Characteristic
Microbiologically
confirmed
TB patients
(n ¼ 19)
n (%)
Non-TB
patients
(n ¼ 199)
n (%) P value
Age, years, median [IQR] 13 [9–15] 11 [8–13]
Female sex 12 (63) 111 (56) 0.56
Age, years
5–9 5 (26) 95 (48) 0.07
10–16 14 (74) 104 (52) 0.07
History of contact 4 (21) 47 (24) 0.77
History of TB 2 (11) 15 (8) 0.65
Positive HIV status 13 (68) 98 (55)* 0.28
On ART 7 (54) 48 (49) 0.74
Presenting symptoms
Fever 14 (74) 91 (47)† 0.03
Weight loss 13 (81)‡ 109 (60)§ 0.10
Night sweats 8 (44)¶ 76 (40)# 0.74
*20 non-TB patients without documented proof of HIV testing excluded.
† 5 non-TB patients with no history of fever excluded.
‡ 3 TB patients with no history of weight loss excluded.
§ 18 non-TB patients with no history of weight loss excluded.
¶ 1 TB patient with no history of night sweats excluded.
# 11 non-TB patients with no history of night sweats excluded.
TB ¼ tuberculosis (pulmonary); IQR ¼ interquartile range; HIV ¼ human
immunodeficiency virus; ART¼antiretroviral therapy.
Figure Venn diagram for positive smear microscopy, culture
and Xpert on IS. This diagram includes 19 children with
microbiologically confirmed tuberculosis. Numbers in brackets
indicate HIV-infected cases. All the 19 microbiologically con-
firmed children received anti-tuberculosis treatment. IS ¼
induced sputum; HIV¼ human immunodeficiency virus.
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positive in 12.4% (14/113) of cases vs. 3.5% (3/87) in
non-HIV-infected children (P ¼ 0.025). Of the 17
stool Xpert-positive cases, 13 (76.5%) had microbi-
ologically confirmed TB. Stool Xpert detected re-
spectively 60% (3/5), 66.7% (6/9) and 86.7% (13/15)
of smear-positive, culture-positive and IS Xpert-
positive TB cases. Stool Xpert detected 13/19 (68%)
microbiologically confirmed TB cases and was
negative in 195/199 (98%) children with negative
results on microbiologically tests (Table 2). Of the 19
microbiologically confirmed TB cases, stool Xpert
identified 76.9% (10/13) of HIV-infected vs. 50% (3/
6) of non-HIV-infected cases (P¼ 0.241), and 71.4%
(10/14) of children aged 710 years vs. 60% (3/5) of
those aged ,10 years (P¼ 0.637).
Four (2.0%) of the 199 children with microbio-
logically negative results were stool Xpert-positive
(Table 2). The four children with a stool Xpert but
negative IS Xpert and culture were all HIV-infected,
had no history of TB and no history of contact with a
TB index patient. Two (50%) of the four children
received a clinical diagnosis and were the only ones
with a positive stool Xpert among 13 clinically
diagnosed children. Of these two children, one
(50%) had clinical improvement at 2 months of
anti-tuberculosis treatment (determined after the
study). Of 186 children not commenced on treat-
ment, two (1.1%) were stool Xpert-positive; clinical
improvement could not be reliably determined after
the study.
DISCUSSION
The main finding of the study is that Xpert testing on
stool identified 68% of microbiologically confirmed
TB and was negative in 98% of children with negative
microbiological results. Similar to findings by Nicol
et al.,16 this study showed that Xpert on stool was
more sensitive in HIV-infected than in non-HIV-
infected children. Although the test failed to identify
32% of TB cases, it may be of more value in HIV-
infected children, who run a high risk of acquiring
TB, as well as high risk of disease progression. Marcy
et al. reported a sensitivity of 62% for stool Xpert
testing among HIV-infected children.19 Smear mi-
croscopy, the routinely available test at primary care
centres, has a sensitivity of ,10–15% in children
with proven TB,20–22 and its performance is even
poorer in those with HIV infection.23
Xpert is currently being rolled out in many parts of
southern Africa for use as an initial test for TB
diagnosis. The test offers rapid diagnosis and detects
more cases than smear microscopy in children.7–9,21
However, its limitation is that it requires a sputum
sample, which is difficult to obtain freely expectorat-
ed from children. At primary care level, sputum
induction in children is rarely attempted, and when it
is performed the quality of the specimen varies
depending on the personnel, resulting in variable test
sensitivity. Welday et al. showed that stool Xpert
testing in children detected all of the sputum smear-
positive cases.24 In our study, stool Xpert testing
helped to identify most of the IS Xpert-positive cases,
suggesting that when a sputum sample is not readily
available a stool sample, which is easier to collect,
may be used with the Xpert test. However, the
diagnostic yield of the stool Xpert test still requires
optimisation.
The inability of stool Xpert to detect six of the
microbiologically confirmed cases may be due to
Table 2 Diagnostic performance of stool Xpert in A) microbiologically determined TB cases and in B) clinically diagnosed TB cases
A)
Microbiological TB result (n ¼ 218)
Positive Negative
All
(n ¼ 19)
n (%)
HIVþ
(n ¼ 13)
n (%)
HIV–
(n ¼ 6)
n (%)
,10 years
(n ¼ 5)
n (%)
710 years
(n ¼ 14)
n (%)
All
(n ¼ 199)
n (%)
HIVþ
(n ¼ 98)*
n (%)
HIV–
(n ¼ 81)*
n (%)
,10 years
(n ¼ 95)
n (%)
710 years
(n ¼ 104)
n (%)
Stool Xpert test
Positive 13 (68) 10 (76.9) 3 (50) 3 (60) 10 (71.4) 4 (2.0) 4 (4.1) 0 1 (1.1) 3 (2.9)
Negative 6 (32.6) 3 (23.1) 3 (50) 2 (40) 4 (28.6) 195 (98) 94 (95.9) 81 (100) 94 (98.9) 101 (97.1)
B)
Clinically diagnosed TB
All
(n ¼ 13)
n (%)
HIVþ
(n ¼ 7)†
n (%)
HIV–
(n ¼ 3)†
n (%)
,10 years
(n ¼ 6)
n (%)
710 years
(n ¼ 7)
n (%)
Stool Xpert test
Positive 2 (15.4) 2 (28.6) 0 0 2 (28.6)
Negative 11 (84.6) 5 (71.4) 3 (100) 6 (100) 5 (71.4)
* 20 children without HIV test result excluded.
† 3 children without HIV test result excluded.
TB¼ tuberculosis (pulmonary); HIV¼ human immunodeficiency virus;þ¼ positive; –¼ negative.
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interference by PCR inhibitors present in stool
samples. Emerging evidence suggests that using larger
sample volumes, of 0.6 g25 and 2 cm3,26 and pre-
treatment with a stool-processing buffer to inactivate
PCR inhibitors,25 achieves greater diagnostic yield of
the stool Xpert test.
The stool Xpert test performed poorly in the
clinically diagnosed children. Xpert testing has
consistently shown poor performance in clinically
defined probable TB cases in children.27,28 This is
more likely to indicate a limitation of the assay’s
detection limit than a limitation of the sample used, as
clinical microbiologically negative TB cases are more
likely to have paucibacillary disease. The two
clinically diagnosed children identified using stool
Xpert were both HIV-infected, again indicating the
potential use of the test in HIV infection.
The main limitation of our study was the lower
than expected TB prevalence, which limited study
power. Second, we used one stool sample collected at
random; a second sample has been shown to have
incremental value in detecting additional cases.6,7,22
Our findings cannot be generalised to all children, as
the performance of the stool Xpert test was assessed
only in children aged 5–16 years. Different results
may occur with children aged ,5 years, in whom TB
disease presentation is markedly different.
In conclusion, the stool Xpert test holds promise as
an alternative to sputum Xpert testing, particularly in
HIV-infected children. Stool collection is easier and
relatively safe compared to sputum collection, and
may potentially have diagnostic utility if its sensitivity
is optimised. Further studies are required to deter-
mine optimal stool collection times, optimal sample
volumes, the need for a second sample, concentration
techniques that allow maximum yield and test
combination algorithms.
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R E S U M E
OB J E C T I F : Evaluer la performance diagnostique du test
XpertwMTB/RIF sur des e´chantillons de selles d’enfants
avec suspicion clinique d’avoir une tuberculose (TB)
pulmonaire dans des structures de soins de sante´
primaires.
S C H E´ M A : Evaluation transversale du diagnostic
enroˆlant des enfants aˆge´s de 5 a` 16 ans pour lesquels
un e´chantillon d’expectoration induite a e´galement e´te´
teste´ pour une confirmation microbiologique de la TB.
Les re´sultats d’un seul e´chantillon de selles teste´ par
Xpert ont e´te´ compare´s a` ceux d’une TB confirme´e par
microbiologie, de´finie comme un re´sultat positif de la
microscopie de crachats et/ou de la culture et/ou de
l’Xpert sur expectoration induite.
R E´ S U LTAT S : Sur 222 enfants enroˆle´s, 218 ont eu des
re´sultats microbiologiques complets. L’aˆge me´dian e´tait
de 10,6 ans (intervalle interquartile 8–13). Une TB a e´te´
confirme´e par microbiologie chez 19/218 (8,7%)
enfants. Parmi ces derniers, 5 (26%), 9 (47%) et 15
(79%), respectivement, ont eu un re´sultat positif de
frottis, de culture et d’Xpert sur expectoration induite.
L’Xpert sur e´chantillon de selles a e´te´ positif dans 13/19
(68%) cas microbiologiquement confirme´s et 4/199
(2%) cas microbiologiquement ne´gatifs. L’Xpert sur
selles a de´tecte´ 76,9% (10/13) des enfants positifs au
virus de l’immunode´ficience humaine (VIH) et 50% (3/
6) des enfants VIH ne´gatifs avec une TB
microbiologique (P¼ 0,241).
C O N C L U S I O N : L’Xpert pourrait eˆtre un test de
de´pistage alternatif potentiel pour les enfants avec
suspicion de TB si l’on ne dispose pas de crachats. Les
strate´gies visant a` optimiser le rendement diagnostique
du test Xpert sur des selles doivent be´ne´ficier d’autres
e´tudes.
R E S UM E N
OB J E T I VO: Evaluar el rendimiento diagno´stico de la
prueba Xpertw MTB/RIF en las muestras de materias
fecales de nin˜os con presuncio´n clı´nica de tuberculosis
(TB) pulmonar, en los consultorios de atencio´n
primaria.
M E´ TODO: Fue este un estudio transversal de evaluacio´n
del diagno´stico de TB en nin˜os de edad de 5–15 an˜os, de
quienes se obtuvo una muestra de esputo inducido con
fines de confirmacio´n microbiolo´gica. Se compararon
los resultados de la prueba Xpert en una muestra u´nica
de materia fecal con los casos de TB confirmada
microbiolo´gicamente mediante un resultado positivo
de la baciloscopia del esputo, el cultivo o la prueba Xpert
en el esputo inducido.
R E SU LTADOS: De los 222 nin˜os que participaron en el
estudio, 218 contaban con resultados microbiolo´gicos
completos. La mediana de la edad fue 10,6 an˜os
(intervalo intercuartil 8–13). Se obtuvo confirmacio´n
microbiolo´gica del diagno´stico de TB en 19/218 nin˜os
(8,7%). De estos nin˜os, 5 obtuvieron un resultado
positivo de la baciloscopia (26%), 9 un cultivo positivo
(47%) y en 15 casos se observo´ un resultado positivo con
la prueba Xpert en la muestra de esputo inducido (79%).
La prueba Xpert en la muestra fecal fue positiva en 13/
19 casos confirmados bacteriolo´gicamente (68%) y en
4/199 sin confirmacio´n microbiolo´gica (2%). Con la
prueba Xpert en muestras de materia fecal se detecto´ el
76,9% de los casos coinfectados por el virus de la
inmunodeficiencia humana (VIH) (10/13) y el 50% de
los nin˜os sin infeccio´n por el VIH (3/6) con TB
confirmada microbiolo´gicamente (P¼ 0,241).
CONC LU S I O´ N: La prueba Xpert en muestras de materia
fecal puede constituir otra opcio´n de pruebas de
deteccio´n en los nin˜os con presuncio´n clı´nica de TB,
cuando no se cuenta con muestras de esputo. Se precisan
nuevas investigaciones sobre las estrategias que puedan
mejorar el rendimiento diagno´stico en estas muestras.
Xpert testing on stool samples from children i
